Ophthalmology Times

Ophthalmology Times company information, Employees & Contact Information

As aging patients increase in number, ophthalmologists and optometrists face regulatory obstacles, reimbursement delays, and limited resources for technology. The tools and knowledge we provide to eyecare professionals help improve the delivery of progressive eye health from provider to patient.
Looking for a particular Ophthalmology Times employee's phone or email?

Ophthalmology Times Questions

News

Throwback Series: The eye that found a cancer - Ophthalmology Times

Throwback Series: The eye that found a cancer Ophthalmology Times

STAAR postpones Alcon merger vote, Broadwood calls for removal of board members - Ophthalmology Times

STAAR postpones Alcon merger vote, Broadwood calls for removal of board members Ophthalmology Times

REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD - Ophthalmology Times

REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD Ophthalmology Times

Q&A: First time results of VOY-101 for geographic atrophy - Ophthalmology Times

Q&A: First time results of VOY-101 for geographic atrophy Ophthalmology Times

Exposure to pesticides and increased risk of AMD - Ophthalmology Times

Exposure to pesticides and increased risk of AMD Ophthalmology Times

Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3 - Ophthalmology Times

Redefining retinal care: Ixo-vec gene therapy for nAMD enters phase 3 Ophthalmology Times

ASRS 2025: ARCHER II, a phase 3 randomized trial of ANX007 in patients with dry AMD and GA - Ophthalmology Times

ASRS 2025: ARCHER II, a phase 3 randomized trial of ANX007 in patients with dry AMD and GA Ophthalmology Times

Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote - Ophthalmology Times

Tensions rise between STAAR and Broadwood as proposed Alcon deal nears vote Ophthalmology Times

FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 - Ophthalmology Times

FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010 Ophthalmology Times

PulseSight doses first patient in PST-611-CT1 - Ophthalmology Times

PulseSight doses first patient in PST-611-CT1 Ophthalmology Times

Alcon agrees to acquire STAAR Surgical - Ophthalmology Times

Alcon agrees to acquire STAAR Surgical Ophthalmology Times

Retinal microvasculature on OCTA may predict coronary artery disease risk - Ophthalmology Times

Retinal microvasculature on OCTA may predict coronary artery disease risk Ophthalmology Times

Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD - Ophthalmology Times

Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD Ophthalmology Times

ARVO 2025: Retina extracellular vesicles in diabetic retinopathy - Ophthalmology Times

ARVO 2025: Retina extracellular vesicles in diabetic retinopathy Ophthalmology Times

FDA approves prednisolone acetate ophthalmic suspension for treating steroid-responsive ocular inflammation - Ophthalmology Times

FDA approves prednisolone acetate ophthalmic suspension for treating steroid-responsive ocular inflammation Ophthalmology Times

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38% - Ophthalmology Times

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38% Ophthalmology Times

Opus Genetics reports positive phase 3 results for phentolamine ophthalmic solution 0.75% - Ophthalmology Times

Opus Genetics reports positive phase 3 results for phentolamine ophthalmic solution 0.75% Ophthalmology Times

European Commission approves aflibercept biosimilar Mynzepli - Ophthalmology Times

European Commission approves aflibercept biosimilar Mynzepli Ophthalmology Times

Q&A: Tarek Hassan, MD, on a new retinotomy technique - Ophthalmology Times

Q&A: Tarek Hassan, MD, on a new retinotomy technique Ophthalmology Times

Structure-function link between ellipsoid zone integrity features and visual acuity in eyes with GA - Ophthalmology Times

Structure-function link between ellipsoid zone integrity features and visual acuity in eyes with GA Ophthalmology Times

EyeCon 2025: Sruthi Arepalli, MD, spotlights a deep-dive orbital tour of the eye - Ophthalmology Times

EyeCon 2025: Sruthi Arepalli, MD, spotlights a deep-dive orbital tour of the eye Ophthalmology Times

Re-Vana and Boehringer Ingelheim launch $1B collaboration to develop extended-release eye therapies - Ophthalmology Times

Re-Vana and Boehringer Ingelheim launch $1B collaboration to develop extended-release eye therapies Ophthalmology Times

EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning - Ophthalmology Times

EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning Ophthalmology Times

Contivue port delivery platform for nAMD receives CE mark - Ophthalmology Times

Contivue port delivery platform for nAMD receives CE mark Ophthalmology Times

SpyGlass Pharma secures $75 million in Series D financing round - Ophthalmology Times

SpyGlass Pharma secures $75 million in Series D financing round Ophthalmology Times

STAAR and Broadwood conflict over proposed Alcon merger continues - Ophthalmology Times

STAAR and Broadwood conflict over proposed Alcon merger continues Ophthalmology Times

Q&A: A VERONA trial update with Yasha S. Modi, MD - Ophthalmology Times

Q&A: A VERONA trial update with Yasha S. Modi, MD Ophthalmology Times

Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times

Ocugen signs term sheet for korean licensing of OCU400 gene therapy Ophthalmology Times

The future of imaging is out of this world - Ophthalmology Times

The future of imaging is out of this world Ophthalmology Times

What to expect from ASRS 2025 - Ophthalmology Times

What to expect from ASRS 2025 Ophthalmology Times

Glaucoma-focused session with Angelo P. Tanna, MD, launches Northwestern University’s “Dinner with the Experts” series - Ophthalmology Times

Glaucoma-focused session with Angelo P. Tanna, MD, launches Northwestern University’s “Dinner with the Experts” series Ophthalmology Times

Procedural Pharmaceuticals in Glaucoma: Focus on Bimatoprost and Travoprost Implants - Ophthalmology Times

Procedural Pharmaceuticals in Glaucoma: Focus on Bimatoprost and Travoprost Implants Ophthalmology Times

Kodiak announces new data from APEX study of KSI-101 - Ophthalmology Times

Kodiak announces new data from APEX study of KSI-101 Ophthalmology Times

FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025 - Ophthalmology Times

FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025 Ophthalmology Times

Neurotech Pharmaceuticals appoints Peter J. McDonnell, MD, to board of directors - Ophthalmology Times

Neurotech Pharmaceuticals appoints Peter J. McDonnell, MD, to board of directors Ophthalmology Times

Scuba divers and surfers face dual light exposure that may accelerate AMD - Ophthalmology Times

Scuba divers and surfers face dual light exposure that may accelerate AMD Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea - Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea Ophthalmology Times

Regeneron’s sBLA for Eylea HD accepted for priority review by FDA - Ophthalmology Times

Regeneron’s sBLA for Eylea HD accepted for priority review by FDA Ophthalmology Times

FDA grants Breakthrough Therapy Designation for Tinlarebant - Ophthalmology Times

FDA grants Breakthrough Therapy Designation for Tinlarebant Ophthalmology Times

Ophthalmology Times® marks 50th anniversary with commemorative issue - GlobeNewswire

Ophthalmology Times® marks 50th anniversary with commemorative issue GlobeNewswire

Bausch + Lomb identifies issue in enVista platform, returns product to market - Ophthalmology Times

Bausch + Lomb identifies issue in enVista platform, returns product to market Ophthalmology Times

EnVision Summit 2025: Glaucoma with co-existing ocular co-morbidities - Ophthalmology Times

EnVision Summit 2025: Glaucoma with co-existing ocular co-morbidities Ophthalmology Times

CORXEL submits NDA for LNZ100 in China for presbyopia treatment - Ophthalmology Times

CORXEL submits NDA for LNZ100 in China for presbyopia treatment Ophthalmology Times

Possible protective role of cannabis in preventing postoperative proliferative vitreoretinopathy after retinal detachment repair - Ophthalmology Times

Possible protective role of cannabis in preventing postoperative proliferative vitreoretinopathy after retinal detachment repair Ophthalmology Times

Study links AMD to higher cardiovascular disease mortality in high-risk patients - Ophthalmology Times

Study links AMD to higher cardiovascular disease mortality in high-risk patients Ophthalmology Times

Using opioids to prevent sneezing and potential ocular tissue damage during sedation and periocular injections - Ophthalmology Times

Using opioids to prevent sneezing and potential ocular tissue damage during sedation and periocular injections Ophthalmology Times

Lupin signs definitive agreement to acquire VISUfarma - Ophthalmology Times

Lupin signs definitive agreement to acquire VISUfarma Ophthalmology Times

FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease - Ophthalmology Times

FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease Ophthalmology Times

Belite Bio concludes phase 3 DRAGON study for Stargardt disease - Ophthalmology Times

Belite Bio concludes phase 3 DRAGON study for Stargardt disease Ophthalmology Times

Yale researchers identify corneal ulcer pathogens by testing tears - Ophthalmology Times

Yale researchers identify corneal ulcer pathogens by testing tears Ophthalmology Times

FDA grants fast track designation to AAVantgarde Bio for AAVB-039 - Ophthalmology Times

FDA grants fast track designation to AAVantgarde Bio for AAVB-039 Ophthalmology Times

Glaucoma techniques advance with innovative viscoelastic delivery - Ophthalmology Times

Glaucoma techniques advance with innovative viscoelastic delivery Ophthalmology Times

FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa - Ophthalmology Times

FDA grants breakthrough therapy designation to Nacuity’s NPI-001 for retinitis pigmentosa Ophthalmology Times

Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye - Ophthalmology Times

Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye Ophthalmology Times

Opthea to lay off approximately 65% of company - Ophthalmology Times

Opthea to lay off approximately 65% of company Ophthalmology Times

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy - Ophthalmology Times

Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy Ophthalmology Times

Alcon agrees to purchase LENSAR - Ophthalmology Times

Alcon agrees to purchase LENSAR Ophthalmology Times

Topcon acquires Intelligent Retinal Imaging Systems, bolstering AI-powered screenings - Ophthalmology Times

Topcon acquires Intelligent Retinal Imaging Systems, bolstering AI-powered screenings Ophthalmology Times

Opus Genetics releases topline results from LYNX-2 evaluating phentolamine ophthalmic solution 0.75% - Ophthalmology Times

Opus Genetics releases topline results from LYNX-2 evaluating phentolamine ophthalmic solution 0.75% Ophthalmology Times

Aldeyra submits third new drug application for reproxalap for the treatment of dry eye disease - Ophthalmology Times

Aldeyra submits third new drug application for reproxalap for the treatment of dry eye disease Ophthalmology Times

EMA grants Orphan designations to MCO-010, FDA grants RMAT in Stargardt disease - Ophthalmology Times

EMA grants Orphan designations to MCO-010, FDA grants RMAT in Stargardt disease Ophthalmology Times

The emerging era of presbyopia-correcting eye drops: What’s next? - Ophthalmology Times

The emerging era of presbyopia-correcting eye drops: What’s next? Ophthalmology Times

OKYO Pharma details next clinical stage of urcosimod development - Ophthalmology Times

OKYO Pharma details next clinical stage of urcosimod development Ophthalmology Times

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint - Ophthalmology Times

Opthea phase 3 clinical trial, COAST, in patients with wet age-related macular degeneration fails to meet primary endpoint Ophthalmology Times

Navigate successful cataract surgery with refractive technology - Ophthalmology Times

Navigate successful cataract surgery with refractive technology Ophthalmology Times

STAAR Surgical files definitive proxy statement on pending merger with Alcon - Ophthalmology Times

STAAR Surgical files definitive proxy statement on pending merger with Alcon Ophthalmology Times

J&J gene therapy treatment fails primary endpoints - Ophthalmology Times

J&J gene therapy treatment fails primary endpoints Ophthalmology Times

Alcon acquires majority interest in Aurion Biotech - Ophthalmology Times

Alcon acquires majority interest in Aurion Biotech Ophthalmology Times

Part 6: Biggest innovations in ophthalmology in 50 years - Ophthalmology Times

Part 6: Biggest innovations in ophthalmology in 50 years Ophthalmology Times

Roche Canada announces Vabysmo (faricimab injection) is now publicly funded for macular edema secondary to RVO on RAMQ - Ophthalmology Times

Roche Canada announces Vabysmo (faricimab injection) is now publicly funded for macular edema secondary to RVO on RAMQ Ophthalmology Times

Alcon completes acquisition of LumiThera - Ophthalmology Times

Alcon completes acquisition of LumiThera Ophthalmology Times

Nicox releases results from Whistler phase 3b trial in IOP-lowering eye drops - Ophthalmology Times

Nicox releases results from Whistler phase 3b trial in IOP-lowering eye drops Ophthalmology Times

Study: No significant long-term benefits found in cocoa extract for AMD - Ophthalmology Times

Study: No significant long-term benefits found in cocoa extract for AMD Ophthalmology Times

STAAR and Broadwood clash over proposed Alcon merger - Ophthalmology Times

STAAR and Broadwood clash over proposed Alcon merger Ophthalmology Times

Updated guidelines enhance choriocapillaris imaging in AMD with SS-OCTA - Ophthalmology Times

Updated guidelines enhance choriocapillaris imaging in AMD with SS-OCTA Ophthalmology Times

Sneak preview: the ASCRS Foundation's blockbuster plans kick off in Los Angeles - Ophthalmology Times

Sneak preview: the ASCRS Foundation's blockbuster plans kick off in Los Angeles Ophthalmology Times

Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence - Ophthalmology Times

Q&A: Jeffrey L. Goldberg, MD, PhD, on the rise of clinical trials centers of excellence Ophthalmology Times

Ophthalmology Times 2024 wrap-up: A year of innovation and insight - Ophthalmology Times

Ophthalmology Times 2024 wrap-up: A year of innovation and insight Ophthalmology Times

Eyeing the brain: How ocular mitochondrial disease may predict dementia risk - Ophthalmology Times Europe

Eyeing the brain: How ocular mitochondrial disease may predict dementia risk Ophthalmology Times Europe

Bausch + Lomb acquires ELIOS system, expanding glaucoma treatment options - Ophthalmology Times

Bausch + Lomb acquires ELIOS system, expanding glaucoma treatment options Ophthalmology Times

Targeted therapies improve care for Demodex blepharitis and OSD - Ophthalmology Times

Targeted therapies improve care for Demodex blepharitis and OSD Ophthalmology Times

Belantamab mafodotin–induced corneal changes in patients with multiple myeloma - Ophthalmology Times

Belantamab mafodotin–induced corneal changes in patients with multiple myeloma Ophthalmology Times

FDA accepts biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD - Ophthalmology Times

FDA accepts biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD Ophthalmology Times

ARVO announces Swathi Kaliki, MD, as recipient of 2025 Ludwig von Sallmann Clinician-Scientist Award - Ophthalmology Times

ARVO announces Swathi Kaliki, MD, as recipient of 2025 Ludwig von Sallmann Clinician-Scientist Award Ophthalmology Times

Relationship between fasting C-peptide and diabetic retinopathy in patients with type 2 diabetes mellitus - Ophthalmology Times

Relationship between fasting C-peptide and diabetic retinopathy in patients with type 2 diabetes mellitus Ophthalmology Times

Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470 - Ophthalmology Times

Nicox and Kowa sign agreement for exclusive rights to glaucoma treatment NCX 470 Ophthalmology Times

Ophthalmology balances the promises and challenges of AI - Ophthalmology Times

Ophthalmology balances the promises and challenges of AI Ophthalmology Times

ARVO announces recipients of the 2025 ARVO Foundation Early Career Clinician-Scientist Awards - Ophthalmology Times

ARVO announces recipients of the 2025 ARVO Foundation Early Career Clinician-Scientist Awards Ophthalmology Times

Full list of topics at the International SPECTRALIS Symposium in Heidelberg, Germany - Ophthalmology Times Europe

Full list of topics at the International SPECTRALIS Symposium in Heidelberg, Germany Ophthalmology Times Europe

Heidelberg Engineering, STAAR, Ziemer to showcase latest technologies at ESCRS 2025 - Ophthalmology Times Europe

Heidelberg Engineering, STAAR, Ziemer to showcase latest technologies at ESCRS 2025 Ophthalmology Times Europe

Imaging the ellipsoid zone line could change the global approach to clinical trials - Ophthalmology Times Europe

Imaging the ellipsoid zone line could change the global approach to clinical trials Ophthalmology Times Europe

European Commission grants marketing authorisation to aflibercept biosimilar EYLUXVI (ALT-L9) - Ophthalmology Times Europe

European Commission grants marketing authorisation to aflibercept biosimilar EYLUXVI (ALT-L9) Ophthalmology Times Europe

An implantable option bridges the gap for patients with AMD - Ophthalmology Times Europe

An implantable option bridges the gap for patients with AMD Ophthalmology Times Europe

Increased paediatric astigmatism prevalence and severity after COVID-19 - Ophthalmology Times Europe

Increased paediatric astigmatism prevalence and severity after COVID-19 Ophthalmology Times Europe

EMA CHMP adopts positive opinion for teprotumumab (Tepezza, Amgen) marketing authorisation application - Ophthalmology Times Europe

EMA CHMP adopts positive opinion for teprotumumab (Tepezza, Amgen) marketing authorisation application Ophthalmology Times Europe

MacuMira launches first Health Canada-approved device for AMD treatment - Ophthalmology Times Europe

MacuMira launches first Health Canada-approved device for AMD treatment Ophthalmology Times Europe

International study illuminates economic burden of late-stage age-related macular degeneration - Ophthalmology Times Europe

International study illuminates economic burden of late-stage age-related macular degeneration Ophthalmology Times Europe

Shaping the future of retinal therapy - Ophthalmology Times

Shaping the future of retinal therapy Ophthalmology Times

Myopia’s global impact, by the numbers - Ophthalmology Times Europe

Myopia’s global impact, by the numbers Ophthalmology Times Europe

Bayer submits EMA application for aflibercept 8 mg third indication, retinal vein occlusion - Ophthalmology Times Europe

Bayer submits EMA application for aflibercept 8 mg third indication, retinal vein occlusion Ophthalmology Times Europe

Top Ophthalmology Times Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant